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More than 10 years ago, the role of adjuvant chemotherapy in
early stage non–small-cell lung cancer (NSCLC) was definitively es-
tablished for stage II and III disease,1-6 whereas subset analyses sug-
gested a benefit in patients with large IB tumors.7 Currently, any
attempt to improve results of cisplatin-based chemotherapy by means
of pharmacogenomics approaches has failed, and results of additional
studies are eagerly awaited.8-10
In the article that accompanies this editorial, Kelly et al11 report
the mature data of the RADIANT trial. It is noteworthy that only 51%
of subjects in the erlotinib arm and 57% in the placebo arm received
adjuvant chemotherapy. This situation was quite likely related to the
relevant proportion of enrolled patients with stage IB disease for which
the value of adjuvant chemotherapy is still debatable in the absence of
prospective data for large IB tumors.
No statistically significant difference was shown in disease-free
survival (DFS), which was the primary endpoint of the study, whereas
a trend suggestive of improved outcomes with erlotinib was demon-
strated in the subgroup of patients (16.5%) with an epidermal growth
factor receptor (EGFR) –sensitizing mutation. EGFR mutation status
was not among the stratification factors. In addition, an imbalance was
observed in some patients’ characteristics, such as performance status,
in the comparison of the control arm in the EGFR mutant subgroup
with the intention-to-treat population. Therefore, no definitive con-
clusion can be drawn.
The choice of DFS as the primary endpoint deserves comment.
Although the correlation between progression-free survival (PFS) and
overall survival (OS) has been demonstrated for advanced NSCLC, in
the recognition of PFS as an acceptable surrogate endpoint for OS,12
the same information is not available for the early-disease setting. For
adjuvant studies, OS remains the preferred primary endpoint, and
DFS may be considered only if a futility-based interim analysis is
planned to drive continuation of the trial or not.
The selection of patients was based on fluorescence in situ hy-
bridization and EGFR immunohistochemistry, which are less sensi-
tive tests for biomarkers than mutation testing. In the IPASS (Iressa
Pan-Asia Study) trial, it was shown that the PFS benefit in patients
with EGFR high copy number was entirely driven by the mutation-
positive subgroup. In the era of personalized therapy, it is challenging
to appropriately design a clinical trial that will preserve overtime the
validity of the study hypothesis, especially in the adjuvant setting,
where prolonged follow-up is needed. On another note, the recent
revision of the lung cancer staging system with significant changes in
stage allocation, and with further changes anticipated, represents an
additional layer of complexity in the data interpretation.
Given the existing evidence, one reasonable clinical question
could be, “Should all patients with resected adenocarcinoma be tested
for EGFR mutation?” The College of American Pathologists/Interna-
tional Association for the Study of Lung Cancer/Association for Mo-
lecular Pathology expert consensus opinion,13 endorsed by the
American Society of Clinical Oncology,14 encourages EGFR and ana-
plastic lymphoma kinase testing at diagnosis for all patients with
early-stage adenocarcinoma. The benefit of this approach is that it
enables rapid initiation of treatment in patients who experience a
recurrence because molecular information is immediately available.
This also favors their enrollment onto clinical trials, and a defini-
tive trial to evaluate erlotinib and crizotinib in molecularly selected
patients is planned in the United States (ALCHEMIST trial;
NCT02201992, NCT02193282). Other randomized trials are ongoing
in China (ADJUVANT; CTONG 1104) and Japan (IMPACT;
WJOG6401L) in patients with completely resected IIIA-II/N2-N1
NSCLC with EGFR mutation who are randomly assigned to receive
gefitinib versus a combination of vinorelbine plus platinum as adju-
vant treatment. The disadvantage is the extra cost incurred by molec-
ular testing of patients with early-stage disease who do not experience
a relapse, as well as the possibility that the molecular profile could
change at the time of relapse.
At the present time, the role of targeted agents as adjuvant therapies
remains largely unknown. Patients with sensitizing mutations might de-
rive more benefit from adjuvant chemotherapy,15 and chemotherapy
may reduce the frequency of EGFR sensitizing mutations, suggesting a
preferred response of EGFR mutated subclones to chemotherapy.16 In a
Japanese phase III study, investigators administered adjuvant gefitinib or
placebofor2yearstopatientswithcompletelyresectedNSCLCinstageIB
to IIIA for 4 to 6 weeks after surgery until recurrence or withdrawal.
Recruitment was stopped after 38 patients were randomly assigned; this
was because of interstitial lung disease.17 In another phase III study,18
researchers compared gefitinib with placebo after cisplatin-based chemo-
therapy.Thisstudywasprematurelyclosedasconsequenceofthenegative
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outcomes of other phase III studies,19,20 but no advantage was detected in
few enrolled patients with EGFR mutant tumors.21
The onset of acquired resistant mutations could be a concern
because they have been frequently observed in EGFR-mutant, ad-
vanced NSCLC treated with EGFR tyrosine kinase inhibitors (TKIs).
In a retrospective study, T790 resistant mutations were more common
in cancers that recurred while patients were receiving an adjuvant
EGFR TKI than in cancers that recurred after the EGFR TKI was
stopped (67% v 0%). Patients who had a recurrence after the EGFR
TKI was stopped were treated again, with significant clinical ben-
efit. In a large, prospective phase II study, patients with completely
resected EGFR mutant tumors received erlotinib for 2 years after
completion of adjuvant chemotherapy. In this trial, 63% of pa-
tients with recurrence underwent repeat biopsy; in only one case
was a T790M resistance mutation detected, and the recurrent cases
were still sensitive to EGFR TKIs.
The optimal duration of adjuvant therapy with EGFR TKIs re-
mains a matter of debate. So far, in all adjuvant studies to test EGFR
TKIs, the planned duration of therapy has been 2 years, but no state-
ment can be made in this context. Despite the favorable toxicity profile
of EGFR TKIs, no robust data are available for long-time exposure,
and it is unknown how the duration of therapy might correlate with
efficacy in this setting. Data from long-term survivors with advanced
NSCLC treated with EGFR TKIs indicate a good quality of life and
safety, even after 3 years of treatment.22 In the RADIANT study, the
median duration of treatment was only 11.9 months for erlotinib-
treated patients, and the rate of grade 3 rash, diarrhea, and dosage
reductions and interruptions were significantly higher in the experi-
mental arm. Overall, the safety profile did not differ among EGFR-
mutant NSCLCs. These findings should be carefully considered in the
plans for future studies involving patients who might potentially be
cured with surgery plus adjuvant chemotherapy.
In summary, this study represents an additional piece of research
that aims to define the best approach in patients with completely
resected NSCLC and to define the role of EGFR TKIs in this setting.
The authors should be praised for their foresight in designing this type
of trial nearly 10 years ago. The efficacy of adjuvant EGFR TKIs in
patients with mutations must be further investigated in well-designed
randomized trials, such as the already-recruiting ALCHEMIST study
or the randomized phase III clinical trials in EGFR mutation–positive
patients initiated in China (ADJUVANT; CTONG 1104) and Japan
(IMPACT; WJOG6401L).
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